Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivonescimab plus chemotherapy in advanced malignant pleural mesothelioma
NCT07885306Phase 1Active, not recruiting
- Sponsor
- Ruijin Hospital
- Start
- Mar 2025
- Primary completion
- Aug 2026
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ivonescimab in malignant pleural mesothelioma (MPM), sponsored by Ruijin Hospital. Primary endpoint: Dose-Limiting Toxicities at 28 days. Started Mar 2025; status: active, not recruiting.
02
Drugs
ivonescimab
03
Conditions
malignant pleural mesothelioma (MPM)
Beyond the preview
Go deeper on NCT07885306.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07885306.